Ironwood Pharmaceuticals Inc (IRWD)
6.14
-0.18
(-2.85%)
USD |
NASDAQ |
Jun 26, 10:40
Ironwood Pharmaceuticals SG&A Expense (TTM): 164.80M for March 31, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 164.80M |
December 31, 2023 | 158.31M |
September 30, 2023 | 148.04M |
June 30, 2023 | 140.61M |
March 31, 2023 | 118.25M |
December 31, 2022 | 115.99M |
September 30, 2022 | 116.29M |
June 30, 2022 | 115.41M |
March 31, 2022 | 112.34M |
December 31, 2021 | 111.13M |
September 30, 2021 | 116.43M |
June 30, 2021 | 123.61M |
March 31, 2021 | 131.20M |
December 31, 2020 | 140.00M |
September 30, 2020 | 145.21M |
June 30, 2020 | 151.20M |
March 31, 2020 | 159.80M |
December 31, 2019 | 172.45M |
September 30, 2019 | 183.68M |
June 30, 2019 | 193.30M |
March 31, 2019 | 209.83M |
December 31, 2018 | 220.23M |
September 30, 2018 | 225.82M |
June 30, 2018 | 237.06M |
March 31, 2018 | 235.08M |
Date | Value |
---|---|
December 31, 2017 | 231.18M |
September 30, 2017 | 230.38M |
June 30, 2017 | 213.59M |
March 31, 2017 | 192.72M |
December 31, 2016 | 173.28M |
September 30, 2016 | 149.58M |
June 30, 2016 | 135.03M |
March 31, 2016 | 131.07M |
December 31, 2015 | 125.25M |
September 30, 2015 | 124.32M |
June 30, 2015 | 122.41M |
March 31, 2015 | 118.76M |
December 31, 2014 | 118.33M |
September 30, 2014 | 116.48M |
June 30, 2014 | 118.21M |
March 31, 2014 | 119.78M |
December 31, 2013 | 123.23M |
September 30, 2013 | 127.78M |
June 30, 2013 | 120.36M |
March 31, 2013 | 109.59M |
December 31, 2012 | 92.54M |
September 30, 2012 | 74.23M |
June 30, 2012 | 62.31M |
March 31, 2012 | 53.02M |
December 31, 2011 | 45.92M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
111.13M
Minimum
Dec 2021
193.30M
Maximum
Jun 2019
140.90M
Average
140.31M
Median
SG&A Expense (TTM) Benchmarks
Amicus Therapeutics Inc | 289.34M |
Insmed Inc | 357.69M |
Altimmune Inc | 18.92M |
Cassava Sciences Inc | 15.84M |
InfuSystems Holdings Inc | 59.82M |